Top of the Street: Hensoldt, Unilever, Evonik, dsm-firmenich, IMCD, AAK

By Reuters News

A round-up of notable broker activity this morning from Europe's top-ranked* analysts:

** J.P. Morgan upgrades German defence electronics maker Hensoldt HAGG.DE to "overweight" from "neutral"; says it has among the most attractive product portfolios in the European defence sector and has made required investments to facilitate strong sales

** Deutsche Bank raises British consumer goods giant Unilever ULVR.L to "buy" from "hold"; says company offers a balance of transformation potential, earnings confidence and liquidity benefits to hedge AI risk in a balanced portfolio

** Jefferies cuts Germany's Evonik Industries EVKn.DE to "hold" from "buy"; sees earnings improvement in 2026 as temporary rather than structural

** Jefferies downgrades European chemicals maker dsm-firmenich DSFIR.AS to "hold" from "buy"; views current valuation multiple as full

** Jefferies cuts Dutch ingredients maker IMCD IMCD.AS to "hold"; sees moderate return to organic growth, supporting broadly stable gross margins and a gradual recovery in conversion and EBITA margins

INITIATIONS AND REINSTATEMENTS

** Jefferies initiates Swedish plant-based oils and fats maker AAK with "hold" rating; says weak volumes and pricing pressure weigh on near-term earnings

(*Analyst rankings from Thomson Reuters StarMine. The scale is from 1-star to 5-star with 5 being the best. Analysts are ranked on earnings accuracy as well as relative performance of recommendations over trailing 12-month & 24-month periods.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.